TABLE 1.

Target endpoints for Lynch Syndrome screening in the colorectal cancer specialty clinic.

Outcome measures	Conventional care 2/28/13-6/30/13	Universal tumor screening 7/1/13-12/31/13
New colorectal cancer cases seen	30	44
Received screening	9/30 (30%)	32/44 (73%)
MSI + IHC	6 (67%)	23 (74%)
MSI only	1 (11%)	5 (16%)
IHC only	2 (22%)	3 (10%)
Did not have screening	21/30 (70%)	13/44 (30%)
Prior screening or Lynch syndrome diagnosis	0	5 (39%)
Patient declined	0	3 (23%)
Insurance non-coverage	0	3 (23%)
Reason unknown	21 (100%)	2 (15%)
Genetics evaluation	4	10
Same day appointment offered	0	3

MSI = microsatellite instability; IHC = immunohistochemistry